LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
563
via finance.yahoo.comBusiness & Companies

Revolution Medicines wins EU approval for Rasonque in pancreatic cancer

FROM THE WIRE · FINANCE.YAHOO.COM

Revolution Medicines RVMD announced that the European Commission (EC) has approved its once-daily oral pill Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy. The approval covers…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe European approval of an oral cancer drug expands Revolution Medicines' market, a positive for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The European Commission approved Rasonque (daraxonrasib) for metastatic PDAC.
  2. 02The approval covers adults who received at least one prior systemic therapy.
  3. 03The phase III RASolute 302 study showed a 60% reduction in risk of death versus chemotherapy.
  4. 04The FDA had already approved the drug for a similar indication in August 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.